Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Macugen
Pegaptanib is an anti-angiogenic oligonucleotide drug used to treat neovascular (wet) age-related macular degeneration (AMD). It is a pegylated modified oligonucleotide that binds to and inhibits the activity of vascular endothelial growth factor (VEGF), a protein that plays a key role in the formation of new blood vessels. By inhibiting VEGF, pegaptanib helps to slow or stop the growth of abnormal blood vessels in the eye that can leak fluid and cause vision loss in wet AMD.
Treatment of neovascular (wet) age-related macular degeneration.
Outcome:
Severe adverse reaction
Mechanism:
Unknown
Outcome:
Potential for increased intraocular pressure or inflammation.
Mechanism:
Additive effects on intraocular pressure.
Outcome:
No significant interaction expected.
Mechanism:
Unknown
Most likely new formulation: sustained-release intravitreal implant (Year: 2028, 30% confidence)
Based on historical data and current trends, there is a low likelihood of any significant changes to pegaptanib's regulatory status in the near future.
Anti-angiogenic agent, oligonucleotide
Aptamer